Study: NCT02977286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol Oral Tablet
Description: Naloxegol Oral Tablet 25 mg (or 12.5 mg) po (enteral) daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet po (enteral) twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docusate Sodium 100 Mg oral capsule [Colace]
Description: Docusate Sodium 100 mg po (enteral) twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docusate Sodium 100 Mg oral capsule [Colace]
Description: Docusate Sodium 100 mg po (enteral) twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Senna 217 Mg Oral Tablet
Description: Senna 127 mg oral tablet daily if no spontaneous bowel movement \>/=3 days after scheduled opioid initiation; increase to two senna 127 mg tables if no no spontaneous bowel movement \>/=4 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement \>/=5 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement \>/=6 days after scheduled opioid initiation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Senna 217 Mg Oral Tablet
Description: Senna 127 mg oral tablet daily if no spontaneous bowel movement \>/=3 days after scheduled opioid initiation; increase to two senna 127 mg tables if no no spontaneous bowel movement \>/=4 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement \>/=5 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement \>/=6 days after scheduled opioid initiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycols
Description: Polyethylene Glycols 17 g daily if no spontaneous bowel movement \>/=3 days after scheduled opioid initiation; increase to 34 g daily if no spontaneous bowel movement \>/=4 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement \>/= 5 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement \>/= 6 days after scheduled opioid initiation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polyethylene Glycols
Description: Polyethylene Glycols 17 g daily if no spontaneous bowel movement \>/=3 days after scheduled opioid initiation; increase to 34 g daily if no spontaneous bowel movement \>/=4 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement \>/= 5 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement \>/= 6 days after scheduled opioid initiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl 10 mg Suppository
Description: Insert one suppository if no spontaneous bowel movement \>/=4 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement \>/= 5 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement \>/= 6 days after scheduled opioid initiation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bisacodyl 10 mg Suppository
Description: Insert one suppository if no spontaneous bowel movement \>/=4 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement \>/= 5 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement \>/= 6 days after scheduled opioid initiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Citrate Oral Liquid Product
Description: Administer one 10 oz bottle if no spontaneous bowel movement \>/= 5 days after scheduled opioid initiation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium Citrate Oral Liquid Product
Description: Administer one 10 oz bottle if no spontaneous bowel movement \>/= 5 days after scheduled opioid initiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Description: Administer 8 mg or 16 mg (depending on subject's weight) subcutaneously x 1 if no spontaneous bowel movement \>/= 6 days after scheduled opioid initiation, consult surgery/gastroenterology and discontinue study medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylnaltrexone
Description: Administer 8 mg or 16 mg (depending on subject's weight) subcutaneously x 1 if no spontaneous bowel movement \>/= 6 days after scheduled opioid initiation, consult surgery/gastroenterology and discontinue study medication.